Corvus Pharmaceuticals, Inc. (CRVS) financial statements (2021 and earlier)
Company profile
| Business Address |
863 MITTEN ROAD BURLINGAME, CA 94010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 44 | 51 | 59 | 69 | 78 | 86 | 97 | ||
| Cash and cash equivalents | 16 | 23 | 21 | 23 | 5 | 9 | 30 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 28 | 28 | 39 | 45 | 73 | 77 | 67 | ||
| Prepaid expense | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| Other current assets | 0 | 0 | 0 | 1 | 0 | 1 | 1 | ||
| Other undisclosed current assets | 0 | 0 | 0 | 1 | 1 | 1 | 0 | ||
| Total current assets: | 45 | 53 | 61 | 70 | 79 | 88 | 98 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 2 | 2 | 2 | 2 | 2 | 2 | 3 | ||
| Property, plant and equipment | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||
| Long-term investments and receivables | 37 | ||||||||
| Long-term investments | 37 | ||||||||
| Other noncurrent assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||
| Total noncurrent assets: | 40 | 3 | 4 | 4 | 4 | 5 | 5 | ||
| TOTAL ASSETS: | 86 | 56 | 64 | 74 | 84 | 92 | 103 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6 | 6 | 5 | 6 | 4 | 4 | 4 | ||
| Accounts payable | 3 | 3 | 3 | 3 | 2 | 2 | 3 | ||
| Accrued liabilities | 0 | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Employee-related liabilities | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||
| Debt | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Other undisclosed current liabilities | 6 | 5 | 5 | 5 | 5 | 4 | 5 | ||
| Total current liabilities: | 12 | 12 | 12 | 12 | 10 | 10 | 11 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | 2 | 2 | 2 | 2 | 3 | 3 | ||
| Operating lease, liability | 1 | 2 | 2 | 2 | 2 | 3 | 3 | ||
| Other undisclosed noncurrent liabilities | (1) | ||||||||
| Total noncurrent liabilities: | 2 | 2 | 2 | 2 | 3 | 3 | |||
| Total liabilities: | 13 | 14 | 13 | 14 | 13 | 12 | 13 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 72 | 42 | 51 | 60 | 71 | 80 | 90 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 295 | 293 | 291 | 290 | 288 | 286 | 285 | ||
| Accumulated other comprehensive income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Accumulated deficit | (223) | (250) | (241) | (230) | (217) | (206) | (195) | ||
| Total stockholders' equity: | 72 | 42 | 51 | 60 | 71 | 80 | 90 | ||
| TOTAL LIABILITIES AND EQUITY: | 86 | 56 | 64 | 74 | 84 | 92 | 103 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (10) | (10) | (11) | (13) | (11) | (12) | (14) | |
| Operating loss: | (10) | (10) | (11) | (13) | (11) | (12) | (14) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 37 | |||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 28 | (10) | (11) | (13) | (11) | (12) | (14) | |
| Other undisclosed income from continuing operations before income taxes | 0 | 2 | ||||||
| Income (loss) before gain (loss) on sale of properties: | 28 | (10) | (11) | (13) | (9) | (12) | (14) | |
| Other undisclosed net income (loss) | (1) | 0 | (2) | |||||
| Net income (loss): | 27 | (10) | (11) | (13) | (11) | (12) | (14) | |
| Other undisclosed net income attributable to parent | 0 | 0 | 1 | 1 | ||||
| Net income (loss) available to common stockholders, diluted: | 27 | (10) | (11) | (13) | (11) | (11) | (13) | |
Comprehensive Income ($ in millions)
| 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 27 | (10) | (11) | (13) | (11) | (12) | (14) | |
| Comprehensive income (loss): | 27 | (10) | (11) | (13) | (11) | (12) | (14) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | 0 | 0 | 0 | (0) | 1 | 1 | |
| Comprehensive income (loss), net of tax, attributable to parent: | 27 | (10) | (11) | (13) | (11) | (11) | (13) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.